Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Clinicians quantify burning, stabbing, and evoked pain by combining intensity ratings (0 to 10 scales), validated neuropathic screening tools such as painDETECT, DN4, and LANSS, and bedside or formal quantitative sensory testing that grades responses to light touch, pinprick, heat, cold, and pressure. They also map where symptoms occur, record triggers like clothing contact or temperature change, and note allodynia (pain from a normally painless stimulus) versus hyperalgesia (exaggerated pain), which helps separate nerve-driven pain from inflammatory or musculoskeletal sources and points toward imaging, blood work, or nerve conduction studies. Scores alone are not a diagnosis, and there are several important factors that shift how results are interpreted, so see below to understand more before drawing conclusions about your own symptoms.
Because these measurements depend heavily on your exact pattern of sensations, timing, and triggers, organizing that detail before an appointment makes your evaluation faster and more accurate. Take a free, instant, online symptom check to clarify what your pain descriptors may point to and to plan sensible next steps.
Last reviewed for medical accuracy: 08/19/2026
Accurately measuring the quality and intensity of pain is a critical step in tailoring effective treatments for people with fibromyalgia and other conditions that include a neuropathic component. Burning, stabbing, and evoked pain each describe different nerve-related sensations that can significantly impact daily life. The Neuropathic Pain Symptom Inventory (NPSI) is one validated tool clinicians use to quantify these symptoms, track treatment response, and guide next steps in care.
Neuropathic pain arises from damage or dysfunction in the nervous system. Common descriptors include:
In fibromyalgia, central sensitization—an increased responsiveness of pain pathways in the spinal cord and brain—can magnify these symptoms. Identifying and quantifying each pain type helps distinguish whether symptoms stem primarily from central mechanisms, peripheral nerve injury, or a combination.
The NPSI is a patient-reported questionnaire specifically designed to capture the variety and severity of neuropathic pain symptoms. It has been validated in multiple languages and settings, including patients with fibromyalgia. Key features include:
Clinicians sum the item scores to generate a total NPSI score (range 0–100), or analyze sub-scores for distinct symptom clusters:
While fibromyalgia is predominantly a central sensitization disorder, some patients report features classically seen in neuropathic pain. Using the NPSI in fibromyalgia can:
In clinical studies, fibromyalgia patients with higher NPSI evoked pain scores have shown better responses to medications such as pregabalin, suggesting the NPSI can help predict which treatments may work best.
Once NPSI data have been collected, clinicians and patients collaborate on a personalized management plan. Key next steps include:
Review and interpret NPSI scores
Conduct a focused clinical examination
Consider adjunctive diagnostic tests if indicated
Tailor pharmacologic treatment
Incorporate non-pharmacologic strategies
Set realistic goals and timelines
Regular follow-up appointments allow you and your clinician to:
Consistent tracking helps maintain motivation, provides objective feedback, and empowers you to participate actively in your care.
Beyond clinic visits, self-monitoring can enhance understanding of pain triggers, fluctuations, and treatment effects. Consider:
These tools can highlight patterns—such as weather changes, sleep quality, or stress—that influence burning, stabbing, and evoked pain.
Most neuropathic pain management can safely proceed on an outpatient basis. However, you should contact your doctor or seek urgent care if you experience:
Always discuss any symptom that feels unusual or worsening, as early evaluation can prevent complications.
Effective communication is key. At your next appointment:
A collaborative approach ensures that treatment decisions align with your goals and life circumstances.
Quantifying burning, stabbing, and evoked pain using the NPSI provides a clear roadmap for targeted, evidence-based treatment in fibromyalgia and other neuropathic conditions. By partnering closely with your clinician—tracking symptoms, reviewing scores, and adjusting therapies—you can achieve meaningful pain relief and improved function.
If your pain feels unmanageable at any point, or if you notice serious new symptoms, please speak to a doctor right away. Your health and safety come first, and professional guidance is essential for life-threatening or rapidly worsening issues.
(References)
* Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001 May;92(1-2):147-57. doi: 10.1016/s0304-3959(00)00482-6. PMID: 11323136.
* Márquez JO. Neuropathic pain. Arq Neuropsiquiatr. 2009 Dec;67(4):1166-7; author reply 1167. doi: 10.1590/s0004-282x2009000600039. PMID: 20069240.
* Haanpää M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, Cruccu G, Hansson P, Haythornthwaite JA, Iannetti GD, Jensen TS, Kauppila T, Nurmikko TJ, Rice ASC, Rowbotham M, Serra J, Sommer C, Smith BH, Treede RD. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011 Jan;152(1):14-27. doi: 10.1016/j.pain.2010.07.031. Epub 2010 Sep 19. PMID: 20851519.
* Garcia D. Gabapentin for Chronic Neuropathic Pain. Am Fam Physician. 2015 Dec 1;92(11):Online. PMID: 26760423.
* Arendt-Nielsen L, Morlion B, Perrot S, Dahan A, Dickenson A, Kress HG, Wells C, Bouhassira D, Drewes AM. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018 Feb;22(2):216-241. doi: 10.1002/ejp.1140. Epub 2017 Nov 5. PMID: 29105941.
* Sommer C, Üçeyler N. Small-Fiber-Neuropathien. Fortschr Neurol Psychiatr. 2018 Aug;86(8):509-518. doi: 10.1055/a-0648-0450. Epub 2018 Aug 20. PMID: 30125923.
* Bouhassira D. Neuropathic pain: Definition, assessment and epidemiology. Rev Neurol (Paris). 2019 Jan-Feb;175(1-2):16-25. doi: 10.1016/j.neurol.2018.09.016. Epub 2018 Oct 29. PMID: 30385075.
* Fehér G, Nemeskéri Z, Pusch G, Zádori I, Bank G, Gurdán Z, Mészáros J, Mák K, Tibold A, Komoly S. [Chronic orofacial pain]. Orv Hetil. 2019 Jul;160(27):1047-1056. doi: 10.1556/650.2019.31432. PMID: 31264469.
* Tafelski S. [Differentiate neuropathic pain]. Anaesthesist. 2021 Dec;70(12):991-992. doi: 10.1007/s00101-021-01049-9. Epub 2021 Dec 2. PMID: 34854964.
* Mulvey MR, Paley CA, Schuberth A, King N, Page A, Neoh K. Neuropathic Pain in Cancer: What Are the Current Guidelines? Curr Treat Options Oncol. 2024 Sep;25(9):1193-1202. doi: 10.1007/s11864-024-01248-7. Epub 2024 Aug 5. PMID: 39102168; PMCID: PMC11416366.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.